ArticleScientific reports2026
Gabapentsal ameliorate cisplatin-induced vomiting in pigeons: neurochemical evidences and the involvement of serotonin and dopamine modulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cisplatin is used for treatment of various carcinomas in clinics but is associated with the adverse effects of nausea and vomiting. We investigated the antiemetic effect of gabapentsal; a gabapentinoid derivative against cisplatin (10 mg/kg) induced vomiting in pigeons and the neurochemical mechanisms centrally and peripherally and the involvement of dopaminergic receptors. Established video recording setup was used for behavioral experiments while High Performance Liquid Chromatography system coupled with electrochemical detector (HPLC-ECD) was used for the quantification of neurotransmitters 5-hydroxytryptamine (5HT) and its metabolite; 5-hydroxy indole acetic acid (5-HIAA), dopamine (DA) and its metabolites; dihydroxy phenyl acetic acid (DOPAC), homovanillic acid (HVA) and noradrenaline (NA) centrally in brain stem while, peripherally in small intestine. Cisplatin (10 mg/kg i.v.) induced emesis without lethality up to the observation period (3 h.). Gabapentsal attenuated cisplatin induced emesis ~ 77.22%; the standard drug, gabapentin (GB; 100 mg/kg), produced ~ 57.55% reduction. Gabapentsal suppressed (p < 0.05 - p < 0.01) the concentration of 5HT and 5-HIAA in the brain stem and intestine. In continuation, a decline (P < 0.05 - p < 0.01) in the concentration of DA and its metabolite DOPAC in the brain stem while DA concentration was decreased (p < 0.05) in the intestine only. The standard gabapentin (100 mg/kg) decreased (p < 0.05) the concentration of 5HT and NA in the intestine only. Furthermore; gabapentsal attenuated (p < 0.001) quinpirole (3 mg/kg) induced vomiting but no effect on neurotransmitters and their metabolites was noted. In conclusion, gabapentsal has antiemetic activity against cisplatin and quinpirole induced vomiting mediated by serotonergic and dopaminergic components centrally and peripherally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.